HCW Biologics debuted the results from its preclinical study of HCW11-018b, the Company’s lead T-cell engager product candidate, that highlights the uniqueness and advantages of its second-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback